Delayed Puberty in Boys
Constitutional Delay vs Hypogonadotropic vs Hypergonadotropic Causes & Evaluation
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (clinical condition; some therapies are off-label/approved drugs)
Reference only. Not medical advice.
What can go wrong
The main risk is diagnostic: under-treating a permanent hypogonadism (with bone-density, growth and psychosocial consequences) or over-treating benign constitutional delay. Short courses of low-dose testosterone used to induce/accelerate puberty can advance bone age and, if mismanaged, compromise final height; they should be specialist-directed. Self-administered testosterone in an adolescent can suppress the very axis under evaluation and is unsafe.
This is something to take to a clinician. The Atlas can tell you what is known about delayed puberty in boys in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Delayed puberty in boys is conventionally defined as no testicular enlargement (volume <4 mL) by age 14, or failure to progress thereafter. The dominant cause, roughly 60-65% of cases, is constitutional delay of growth and puberty (CDGP), a benign variant of normal timing that is often familial and ultimately self-resolving. The key clinical challenge is distinguishing CDGP from permanent hypogonadotropic hypogonadism (a central/pituitary signaling failure, e.g. Kallmann syndrome) and from hypergonadotropic (primary testicular) failure such as Klinefelter syndrome or prior chemotherapy/orchitis. The distinction matters because CDGP needs reassurance or short-term therapy, whereas permanent hypogonadism needs lifelong management.
Late bloomer, broken signal, or failing gonad? The fork that decides the workup.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Evaluation pivots on gonadotropins. Low/normal LH and FSH with low testosterone indicate a hypogonadotropic (central) picture, which is shared by both benign constitutional delay and permanent congenital HH, making them genuinely hard to separate biochemically in early adolescence. High LH and FSH with low testosterone indicate hypergonadotropic (primary gonadal) failure. Supporting tests include bone age (delayed in CDGP), morning testosterone, prolactin, thyroid function, IGF-1, karyotype (for suspected Klinefelter), pituitary MRI when central disease or tumor is suspected, and a sense of smell (anosmia points to Kallmann). Inhibin B and AMH help gauge Sertoli/testicular reserve.
What the marketing leaves out
No single test cleanly separates CDGP from isolated congenital HH at presentation, because both can show low gonadotropins. Clues favoring permanent HH include micropenis or cryptorchidism at birth, anosmia, very low inhibin B/AMH, absence of any spontaneous progression, and a relevant family/genetic history. GnRH/GnRH-agonist and hCG stimulation tests and inhibin B have been studied to improve discrimination but remain imperfect; time and observation often provide the answer, which is why short courses of low-dose testosterone are used both to treat distress and as a pragmatic bridge.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Testicular volume / pubertal staging
- Bone age
- Morning LH, FSH, testosterone
- Inhibin B / AMH where indicated
- Karyotype and MRI when permanent cause suspected
What people get wrong
Often saidA teen with no puberty just needs testosterone for life
ActuallyMost are constitutional delay and will enter puberty spontaneously; lifelong therapy is reserved for confirmed permanent hypogonadism.
Often saidLow gonadotropins prove permanent hypogonadism
ActuallyThey are equally consistent with benign constitutional delay; the two can be biochemically indistinguishable early on.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- Can a single reliable test separate CDGP from congenital HH at age 14?
- What are the long-term bone and psychosocial effects of watchful waiting vs early treatment?
At a glance
- Definition
- No testes >=4 mL by age 14
- Most common cause
- Constitutional delay (CDGP), ~60-65%
- Central pattern
- Low LH/FSH + low testosterone (hypogonadotropic)
- Primary pattern
- High LH/FSH + low testosterone (hypergonadotropic)
- Bone age
- Typically delayed in CDGP
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Delayed Puberty in Boys. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Palmert & Dunkel, NEJM review of delayed puberty2012
Authoritative framework for CDGP vs permanent hypogonadism and management
Harrington & Palmert, distinguishing CDGP from IHH2012
Reviewed the diagnostic difficulty and proposed-test performance